Please wait a minute...
文章检索
预防医学  2022, Vol. 34 Issue (8): 757-759    DOI: 10.19485/j.cnki.issn2096-5087.2022.08.001
  专家论坛 本期目录 | 过刊浏览 | 高级检索 |
浙江省防范输入性猴痘疫情的对策建议
林君芬
浙江省疾病预防控制中心公共卫生监测与业务指导所,浙江 杭州 310051
Countermeasures against imported monkeypox epidemic in Zhejiang Province
LIN Junfen
Department of Public Health Surveillance and Advisory, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China
全文: PDF(828 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 2022年5月以来,在中非和西非以外的40多个非地方性流行国家报告了猴痘实验室确诊病例,且已出现人际传播,疫情区域有不断扩大的趋势。本文介绍猴痘病毒特性,分析全球猴痘疫情流行态势和浙江省猴痘疫情输入风险,提出加强入境人员检疫、建立猴痘监测网络、开展健康教育、做好风险研判和各项应急准备等猴痘疫情防范对策建议。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
林君芬
关键词 猴痘监测防控措施浙江省    
Abstract:Since May 2022, laboratory-confirmed cases of monkeypox have been reported in more than 40 non-endemic countries and the epidemic may spread to other countries through human-to-human transmission. This study aims to introduce the characteristics of monkeypox virus and analyze the epidemic situation and the risk of imported cases in Zhejiang Province. Multiple recommendations are proposed to prevent monkeypox epidemics in Zhejiang Province including strengthening entry personnel quarantine, establishing monkeypox monitoring system, carrying out monkeypox-related health education, and making risk assessment and preparation.
Key wordsmonkeypox    surveillance    control strategy    Zhejiang Province
收稿日期: 2022-07-05      修回日期: 2022-07-26      出版日期: 2022-08-10
中图分类号:  R373.1  
基金资助:浙江省重点研发计划项目(2021C03038)
作者简介: 林君芬,主任医师,浙江省疾病预防控制中心公共卫生监测首席专家。主要从事公共卫生监测与预警预测、突发事件公共卫生风险评估、突发应急事件现场处置等疾病预防控制及相关研究工作。现任浙江省疾病预防控制中心公共卫生监测与业务指导所所长,兼任浙江省预防医学会理事、浙江省健康促进与教育协会常务理事、公共卫生监测专委会主任委员、医共体专委会主任委员、社区专委会主任委员等。主持参与多项浙江省重点研发计划项目、浙江省自然科学基金重点项目和国家自然科学基金等项目。获浙江省科技进步奖等各类奖项8项;近5年发表学术论文30多篇,主编(副主编)出版著作6部。
引用本文:   
林君芬. 浙江省防范输入性猴痘疫情的对策建议[J]. 预防医学, 2022, 34(8): 757-759.
LIN Junfen. Countermeasures against imported monkeypox epidemic in Zhejiang Province. Preventive Medicine, 2022, 34(8): 757-759.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2022.08.001      或      http://www.zjyfyxzz.com/CN/Y2022/V34/I8/757
[1] KUGELMAN J R,JOHNSTON S C,MULEMBAKANI P M,et al.Genomic variability of monkeypox virus among humans,Democratic Republic of the Congo[J].Emer Infec Dis,2014,20(2):232-239.
[2] HALANI S,MISHRA S,BOGOCH I I.The monkeypox virus[J/OL].CMAJ,2022,194(24)[2022-07-26].https://doi.org/10.1503/cmaj.220795.
[3] ALAKUNLE E,MOENS U,NCHINDA G,et al.Monkeypox virus in Nigeria:infection biology,epidemiology,and evolution[J/OL].Viruses,2020,12(11)[2022-07-26].https://doi.org/10.3390/v12111257.
[4] BUNGE E M,HOET B,CHEN L,et al.The changing epidemiology of human monkeypox-a potential threat? A systematic review[J/OL].PLoS Negl Trop Dis,2022,16(2)[2022-07-26].https://doi.org/10.1371/journal.pntd.0010141.
[5] SAXENA S K,ANSARI S,MAURYA V K,et al.Re-emerging human monkeypox:a major public-health debacle[J/OL].J Med Virol,2022[2022-07-26].https://doi.org/10.1002/jmv.27902.
[6] Centers for Disease Control and Prevention(CDC).Human monkeypox-Kasai Oriental,Democratic Republic of Congo,February 1996-October 1997[J].MMWR,1997,46(49):1168-1171.
[7] DESSEV G,IOVCHEVA-DESSEV C,BISCHOFF J R,et al.A complex containing p34cdc2 and cyclin B phosphorylates the nuclear lamin and disassembles nuclei of clam oocytes in vitro[J].J Cell Biol,1991,112(4):523-533.
[8] BROWN K,LEGGAT P A.Human monkeypox:current state of knowledge and implications for the future[J/OL].Trop Med Infect Dis,2016[2022-07-26].https://doi.org/10.3390/tropicalmed1010008.
[9] PETERSEN E,ABUBAKAR I,IHEKWEAZU C,et al.Monkeypox-enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era[J].Int J Infect Dis,2019,78:78-84.
[10] PETERSEN B W,KABAMBA J,MCCOLLUM A M,et al.Vaccinating against monkeypox in the Democratic Republic of the Congo[J].Antiviral Res,2019,62:171-177.
[11] GRANT R,NGUYEN L L,BREBAN R.Modelling human-to-human transmission of monkeypox[J].Bull World Health Organ,2020,98(9):638-640.
[12] PETER O J,KUMAR S,KUMARI N,et al.Transmission dynamics of monkeypox virus:a mathematical modelling approach[J/OL].Model Earth Syst Environ,2021,15[2022-07-26].https://doi.org/10.1007/s40808-021-01313-2.
[13] BREMAN J G,KALISA R,STENIOWSKI M V,et al.Human monkeypox,1970-79[J].Bull World Health Organ,1980,58(2):165-182.
[14] REYNOLDS M G,WAUQUIER N,LI Y,et al.Human monkeypox in Sierra Leone after 44-year absence of reported cases[J].Emerg Infect Dis,2019,25(5):1023-1025.
[15] MAHASE E.Seven monkeypox cases are confirmed in England[J/OL].BMJ,2022,17 [2022-07-26].https://doi.org/10.1136/bmj.o1239.
[16] MAHASE E.Monkeypox:what do we know about the outbreaks in Europe and North America?[J/OL].BMJ,2022,20[2022-07-26].https://doi.org/10.1136/bmj.o1274.
[17] ANTINORI A,MAZZOTTA V,VITA S,et al.Epidemiological,clinical and virological characteristics of four cases of monkeypox support transmission through Sexual contact,Italy,May2022[J/OL].Euro Surveill,2022,27(22)[2022-07-26].https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200421.
[18] MAHASE E.Monkeypox:gay and bisexual men with high exposure risk will be offered vaccine in England[J/OL].BMJ,2022,22[2022-07-26].https://doi.org/10.1136/bmj.o1542.
[19] KOZLOV M.Monkeypox goes global:why scientists are on alert[J].Nature,2022,606(7912):15-16.
[20] 林君芬,吴梦娜,吴昊澄,等.浙江省新型冠状病毒肺炎病例流行特征分析[J].预防医学,2020,32(3):217-222.
LIN J F,WU M N,WU H C,et al.Epidemiological characteristics of coronavirus disease 2019 in Zhejiang Province[J].Prev Med,2020,32(3):217-222.
[21] 戚小华,刘碧瑶,王臻,等.浙江省境外输入新型冠状病毒肺炎病例特征[J].预防医学,2021,33(6):541-544.
QI X H,LIU B Y,WANG Z,et al.The characteristics of imported COVID-19 cases from abroad to Zhejiang Province[J].Prev Med,2021,33(6):541-544.
[22] 伊赫亚,李川,王芃,等.全球新型冠状病毒肺炎疫情与早期防控对策[J].预防医学,2020,32(4):325-329.
YI H Y,LI C,WANG P,et al.Recommendation on global prevention and control of coronavirus disease 2019 in the early stage[J].Prev Med,2020,32(4):325-329.
[1] 王璇, 刘社兰, 曹艳丽, 孙琬琬, 丰燕, 凌锋. 2013—2022年浙江省流行性感冒暴发疫情流行特征[J]. 预防医学, 2023, 35(8): 645-648.
[2] 张超, 罗小福, 刘艳, 沈建勇, 徐秦儿, 韩利萍, 马力. 湖州市老年人接种流感灭活疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(8): 701-704.
[3] 马艳艳, 陈小劲, 赵月. 朝阳区3~6岁儿童体质健康调查[J]. 预防医学, 2023, 35(7): 615-619.
[4] 席胜军, 周晓红, 周伟洁, 冯哲伟. 入境人员猴痘预防知识调查[J]. 预防医学, 2023, 35(7): 570-573.
[5] 徐杰, 陈棕棕, 骆水娟, 李欢龙. 富阳区市售食品食源性致病菌监测结果[J]. 预防医学, 2023, 35(7): 624-627.
[6] 潘晓东, 韩见龙, 陈苘. 鸡肉中多种抗生素超高效液相-静电场轨道阱高分辨质谱检测方法[J]. 预防医学, 2023, 35(5): 456-459.
[7] 赵冲, 施文文. 富阳区监测哨点医院急诊就诊伤害病例特征分析[J]. 预防医学, 2023, 35(2): 155-157,161.
[8] 范琦淇, 陈慈玉, 孙晓宁, 吴蔚然, 王娟. 高血压患者家庭血压监测调查[J]. 预防医学, 2023, 35(11): 948-952.
[9] 顾红, 侯晓艳, 祁志刚, 吴明. 2008—2022年崇川区疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(11): 992-996.
[10] 李小勇, 段蕾蕾, 武轶群, 钟节鸣, 林鸿波, 沈鹏, 赵磊. 鄞州区伤害智能监测系统介绍及应用[J]. 预防医学, 2023, 35(11): 1009-1012.
[11] 江伟, 刘艳, 杜渐, 许玉洋, 车鑫仁, 王婧, 王骏, 张学潮, 顾雯雯, 张小平. 2017—2021年杭州市HPV疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 71-73,77.
[12] 张超, 沈建勇, 罗小福, 徐秦儿, 韩利萍. 2015—2021年湖州市MMR疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 74-77.
[13] 程伟, 周晓燕, 余昭, 刘社兰, 潘金仁, 凌锋, 陈恩富. 2016—2019年浙江省流行性感冒超额死亡率分析[J]. 预防医学, 2022, 34(9): 865-869.
[14] 刘迎男, 杨景元, 李慧, 杨虹, 杲柏呈, 高雅, 李向春, 曹猛. 2013—2021年内蒙古自治区五类重点人群丙型肝炎监测结果[J]. 预防医学, 2022, 34(9): 941-945.
[15] 傅天颖, 吴昊澄, 鲁琴宝, 丁哲渊, 王心怡, 杨珂, 吴晨, 林君芬. 2021年浙江省法定传染病疫情分析[J]. 预防医学, 2022, 34(8): 842-847.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed